Novo Nordisk Shares Drop as Company Outlines Long-Term Growth Strategy
On September 21, 2026, Novo Nordisk (NYSE:NVO) shares fell by approximately 6% after the Danish pharmaceutical company outlined its long-term growth strategy and financial targets through 2030. The firm emphasized that these are strategic ambitions rather than formal guidance but aims to match industry peers in compound annual revenue growth while maintaining a stable operating margin. Novo Nordisk plans to launch more than five potential blockbuster drugs by 2030, with its pipeline expected to generate over DKK 150 billion in sales by 2035. The company also aims for significant expansion of oral GLP-1 treatment capacity and patient access goals, targeting 60 million patients globally by the end of this decade. The firm identified a group of major pharmaceutical peers against which it will benchmark its performance over the next five years.
Tickers: $NVO
Topics: growth strategy pharmaceuticals stock price movement